Travere Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 68.22 million compared to USD 51.14 million a year ago. Net loss was USD 35.64 million compared to USD 22.55 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.44 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 0.44 a year ago. For the nine months, revenue was USD 170.24 million compared to USD 147.34 million a year ago. Net loss was USD 128.52 million compared to USD 47.81 million a year ago. Basic loss per share from continuing operations was USD 2.17 compared to USD 1.03 a year ago. Diluted loss per share from continuing operations was USD 2.17 compared to USD 1.03 a year ago.